



Immedica enters into licensing agreement for Ravicti® in China and other Asia-Pacific countries with WinHealth

Torreya advised Immedica on the licensing transaction

Stockholm, Sweden and Hangzhou, China, December 30, 2020

Immedica Pharma AB ("Immedica"), a private European pharmaceutical company, and Hongkong WinHealth Pharma Group CO., Ltd ("WinHealth"), a Chinese company focused on rare diseases, entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti®, in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.

The product, Ravicti®, already approved in Europe and North America, is indicated for treatment of urea cycle disorders ("UCD"), and under the announced partnership, WinHealth is granted a license to register and commercialize the product for UCD in the Territory. This deal strengthens Immedica's growing global footprint by introducing another rare disease collaboration into their network.

Torreya advised Immedica on this transaction. This transaction reinforces Torreya's strength and leadership position in China. Torreya has completed 14 transactions involving a China party since 2018. Due to its dedicated China licensing advisory team and market knowledge, Torreya has rapidly become the most active advisory firm in China licensing in the Life Sciences sector.

ABOUT IMMEDICA PHARMA AB:

For more information about Immedica, please see: www.immedica.com

ABOUT HONG KONG WINHEALTH PHARMA GROUP CO, LTD:

For more information about WinHealth, please see: en.winhealth.hk

Deal Press Release



Torreya Contact

JIE LIU

Managing Director | New York Office

jie.liu@torreya.com | 917.683.4003 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.